| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Outline of Final Research Achievements |
3~5 prostate cancer-associated antigens (PTH-rP,EGFR,EZH2) -derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11, -A31, and -A33) were functionally screened for their potential to induce peptide-specific cytotoxic T lymphocytes (CTLs) from peripheral blood mononuclear cells (PBMCs) of 12 HLA-A3 supertype allele+ prostate cancer patients. As a result, EZH2733-741 peptide was found to efficiently induce peptide-specific CTLs. To test cytotoxicity of CTLs by a standard 6-h 51Cr-release assay, CD8+ T cells were purified from EZH2733-741 peptide-stimulated PBMCs. The EZH2733-741 peptide-stimulated and purified CD8+ T cells from PBMCs of HLA-A3 supertype allele+ prostate cancer patients showed higher cytotoxicity against HLA-A3 supertype allele-expressing LNCaP prostate cancer cells than against parental LNCaP cells.
|
